Literature DB >> 9065658

Complications of cyclophosphamide therapy.

C A Langford1.   

Abstract

Cyclophosphamide is a powerful immunosuppressive agent that is commonly used clinically to treat neoplastic and inflammatory diseases affecting various sites, including the head and neck. The pharmacology of cyclophosphamide is reviewed with an emphasis on its toxicities and strategies for minimizing therapeutic adverse effects. Principles of therapy are discussed and illustrated by the use of cyclophosphamide in the treatment of Wegener's granulomatosis, a form of systemic vasculitis with prominent head and neck manifestations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9065658     DOI: 10.1007/bf01526181

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  50 in total

1.  Proceedings: Cyclophosphamide and the kidney.

Authors:  R A DeFronzo; O M Colvin; H Braine; G L Robertson; P J Davis
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

2.  Pulmonary complications of combination therapy with cyclophosphamide and prednisone.

Authors:  R P Sen; T E Walsh; W Fisher; N Brock
Journal:  Chest       Date:  1991-01       Impact factor: 9.410

Review 3.  The effects of impaired liver function on the elimination of antineoplastic agents.

Authors:  G Koren; K Beatty; A Seto; T R Einarson; M Lishner
Journal:  Ann Pharmacother       Date:  1992-03       Impact factor: 3.154

Review 4.  Acute leukemia following prolonged cytotoxic agent therapy.

Authors:  D A Casciato; J L Scott
Journal:  Medicine (Baltimore)       Date:  1979-01       Impact factor: 1.889

5.  Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis.

Authors:  C A Langford; M C Sneller; C W Hallahan; G S Hoffman; W A Kammerer; C Talar-Williams; A S Fauci; R S Lebovics
Journal:  Arthritis Rheum       Date:  1996-10

6.  Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial.

Authors:  R F Struck; D S Alberts; K Horne; J G Phillips; Y M Peng; D J Roe
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

7.  Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.

Authors:  D T Boumpas; H A Austin; E M Vaughan; C H Yarboro; J H Klippel; J E Balow
Journal:  Ann Intern Med       Date:  1993-09-01       Impact factor: 25.391

8.  Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome.

Authors:  L E Kahl
Journal:  J Rheumatol       Date:  1994-01       Impact factor: 4.666

9.  Effect of cyclophosphamide on the immature rat ovary.

Authors:  K M Ataya; F A Valeriote; A J Ramahi-Ataya
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

10.  Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.

Authors:  C Talar-Williams; Y M Hijazi; M M Walther; W M Linehan; C W Hallahan; I Lubensky; G S Kerr; G S Hoffman; A S Fauci; M C Sneller
Journal:  Ann Intern Med       Date:  1996-03-01       Impact factor: 25.391

View more
  7 in total

1.  Secondary acute myeloid leukemia arising early after cyclophosphamide treatment.

Authors:  Hayretdin Koklu; Abdurrahman Tufan; Yusuf Erkul; Nalan Akyurek; Ramazan Civelek
Journal:  Int J Clin Pharm       Date:  2015-01-23

2.  Polyangiitis overlap syndrome of granulomatosis with polyangiitis (Wegener's granulomatosis) and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Authors:  Hironori Uematsu; Shohei Takata; Katsuo Sueishi; Hiromasa Inoue
Journal:  BMJ Case Rep       Date:  2014-02-27

3.  Systemic and Central Nervous System Vasculitides.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.972

4.  Unexplained hypothermia and bradycardia in two pediatric patients with Wegener's granulomatosis.

Authors:  Lianne M Geerdink; Linda Koster-Kamphuis; Elisabeth A M Cornelissen; Michèl A Willemsen; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2010-08-22       Impact factor: 3.714

Review 5.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

6.  Novel histopathologic predictors for renal outcomes in crescentic glomerulonephritis.

Authors:  Jeong-Hoon Lim; Man-Hoon Han; Yong-Jin Kim; Yena Jeon; Hee-Yeon Jung; Ji-Young Choi; Jang-Hee Cho; Chan-Duck Kim; Yong-Lim Kim; Hajeong Lee; Dong Ki Kim; Kyung Chul Moon; Sun-Hee Park
Journal:  PLoS One       Date:  2020-07-27       Impact factor: 3.240

7.  Histopathological Classification-A Prognostic Tool for Rapidly Progressive Glomerulonephritis.

Authors:  Marta Kantauskaitė; Agnė Laučytė-Cibulskienė; Marius Miglinas
Journal:  Medicina (Kaunas)       Date:  2018-04-17       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.